Financials

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

Sector

25-08-26	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
25-05-19	EnVVeno Medical Names Jennifer Bright CFO	MT
25-03-04	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25-02-24	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
25-02-20	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
25-02-17	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
25-02-13	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
25-01-28	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
25-01-13	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
25-01-13	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
25-01-07	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
24-12-22	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
24-11-14	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

24-04-01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
23-05-31	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
23-01-20	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
22-05-20	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

25-10-14	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
24-11-08	Biolase: Q3 Earnings Snapshot	AQ
24-11-07	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
24-10-01	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
24-08-08	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	2025-09-09
Steven Sandor COO	Chief Operating Officer	46	2022-07-05
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	2016-09-30

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	2017-08-31
Kathleen O'Loughlin BRD	Director/Board Member	75	2021-08-15
Kenneth Yale BRD	Director/Board Member	69	2022-04-27

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE INC	-6.39%	-2.55%	-	-	36
CHURCHILL CAPITAL CORP XI	-7.18%	-9.98%	-	-	877M
EINRIDE AB	-7.65%	-28.98%	-	-	762M
DEEP FISSION, INC.	-13.57%	-5.66%	-	-	734M
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	-0.10%	-	-	642M
CHURCHILL CAPITAL CORP XII	-0.19%	-0.37%	-	-	611M
CANTOR EQUITY PARTNERS IV, INC.	+0.08%	+0.29%	-	-	597M
BAIN CAPITAL GSS INVESTMENT CORP.	+0.20%	0.00%	-	-	596M
CENTIEL AG	-2.39%	-0.69%	+246.67%	-70.82%	593M
Average	-4.11%	-5.73%	+246.67%	-70.82%	676.38M
Weighted average by Cap.	-4.32%	-6.60%	+246.67%	-70.82%